Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes

Oral Oncology

Volumn 49, Issue 6, 2013, Pages 482-491

  Peyrade, Frédéric ^a   Cupissol, Didier ^b   Geoffrois, Lionel ^c   Rolland, Frédéric ^d   Borel, Christian ^e   Ciais, Catherine ^a   Faivre, Sandrine ^f   Guigay, Joël ^g  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b CENTRE VAL D AURELLE   (France)

^c CENTRE ALEXIS VAUTRIN   (France)

^d Institut Cancérologique de L'Ouest   (France)

^e CENTRE PAUL STRAUSS   (France)

^f BEAUJON HOSPITAL   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Cetuximab; Chemotherapy; Metastatic squamous cell carcinoma of the head and neck; Recommendations; Supportive care; Targeted therapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FIGITUMUMAB; FLUOROURACIL; GEFITINIB; METHOTREXATE; PACLITAXEL; PANITUMUMAB; SUNITINIB; TAXANE DERIVATIVE; ZALUTUMUMAB;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; DYSPHAGIA; GASTROSTOMY; GERIATRIC ASSESSMENT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; PALLIATIVE CARE;

EID: 84877058675     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.01.005     Document Type: Review

References (74)

1. J. Ferlay, H.R. Shin, and F. Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. E.E. Vokes, R.R. Weichselbaum, S.M. Lippman, and W.K. Hong Head and neck cancer N Engl J Med 328 1993 184 194
3. C. Jacobs, G. Lyman, and E. Velez-García A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck J Clin Oncol 10 1992 257 263
4. A.A. Forastiere, B. Metch, and D.E. Schuller Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study J Clin Oncol 10 1992 1245 1251
5. J.B. Vermorken, R. Mesia, and F. Rivera Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 2008 1116 1127
6. B.A. Murphy, S. Ridner, N. Wells, and M. Dietrich Quality of life research in head and neck cancer: a review of the current state of the science Crit Rev Oncol Hematol 62 2007 251 267
7. Y.L. Lin, I.C. Lin, and J.C. Liou Symptom patterns of patients with head and neck cancer in a palliative care unit J Palliat Med 14 2011 556 559
8. D.G. Harris, and S.I. Noble Management of terminal hemorrhage in patients with advanced cancer: a systematic literature review J Pain Symptom Manage 38 2009 913 927
9. M. Clavel, J.B. Vermorken, and F. Cognetti Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group Ann Oncol 5 1994 521 526
10. M.K. Gibson, Y. Li, and B. Murphy Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group J Clin Oncol 23 2005 3562 3567
11. J.A. Kish, J.F. Ensley, and J. Jacobs A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck Cancer 56 1985 2740 2744
12. J.B. Vermorken, G. Catimel, and P. De Mulder Randomized phase II trial of weekly methotrexate versus two schedules of three-weekly paclitaxel (Taxol®) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck Proc Am Soc Clin Oncol 18 1999 395a
13. A. Rapidis, N. Sarlis, J.L. Lefebvre, and M. Kies Docetaxel in the treatment of squamous cell carcinoma of the head and neck Ther Clin Risk Manage 4 2008 865 886
14. F. Peyrade, E. Chamorey, and A. Bozec High efficacy of docetaxel (T)-platinum (P)-5fluorouracil (F) combination (TPF) in heavily pretreated metastatic or locally recurrent head and neck squamous cell carcinoma Ann Oncol 17 suppl 9 2006 ix179 ix189
15. J.B. Vermorken, J. Trigo, and R. Hitt Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 25 2007 2171 2177
16. B. Burtness, M.A. Goldwasser, W. Flood, B. Mattar, and A.A. Forastiere Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study J Clin Oncol 23 2005 8646 8654
17. J. Guigay, J. Fayette, A.F. Dillies, C. Sire, J.N. Kerge, and I. Tennevet Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03 J Clin Oncol 2012 30 [suppl; abstr 5505]
18. D. Soulieres, N.N. Senzer, and E.E. Vokes Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 2004 77 85
19. J.S. Stewart, E.E. Cohen, and L. Licitra Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected] J Clin Oncol 27 2009 1864 1871
20. A. Argiris, M. Ghebremichael, J. Gilbert, B. Burtness, and A. Forastiere A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group (ECOG) J Clin Oncol 2009 27 abstr 6011
21. E.E. Cohen, D.W. Davis, and T.G. Karrison Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study Lancet Oncol 10 2009 247 257
22. A. Argiris, A.P. Kotsakis, and S. Kim Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results J Clin Oncol 29 suppl 2011 abstr 5564
23. J.B. Vermorken, J. Stöhlmacher, and I. Davidenko Primary efficacy and safety results of SPECTRUM. A phase 3 trial in patients (pts) with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (PMAB) Ann Oncol 21 suppl 8 2010 viii12 [abstract LBA26]
24. J.B. Vermorken, F. Peyrade, J. Krauss, R. Mesia, E. Remenar, and T.C. Gauler Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial J Clin Oncol 2012 30 [suppl; abstr 5516]
25. W.C. Rose, and R. Wild Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts Clin Cancer Res 10 2004 7413 7417
26. J. Guigay, J. Fayette, and A. Dillies Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): first results of phase II trial GORTEC 2008-03 J Clin Oncol 2011 29 [suppl; abstr 5567]
27. J. Fayette, A. Montella, and S. Chabaud Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution Anticancer Drugs 21 2010 553 558
28. B. Jimenez, J.M. Trigo Perez, and M.I. Saez Medina Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients J Clin Oncol 29 suppl 2011 abstr 5594
29. P. Pfeiffer, D. Nielsen, and J. Bjerregaard Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil Ann Oncol 19 2008 1141 1145
30. J.B. Vermorken, E. Remenar, and C. van Herpen Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 2007 1695 1704
31. M.R. Posner, D.M. Hershock, and C.R. Blajman Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 2007 1705 1715
32. T.J. Smith, J. Khatcheressian, and G.H. Lyman 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 2006 3187 3205
33. M.S. Aapro, J. Bohlius, and D.A. Cameron 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 2011 8 32
34. J.D. Rizzo, M.R. Somerfield, and K.L. Hagerty Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update J Clin Oncol 26 2008 132 149
35. C. Bokemeyer, M.S. Aapro, and A. Courdi EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update Eur J Cancer 43 2007 258 270
36. M.E. Lacouture, E.P. Mitchell, and B. Piperdi Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol 28 2010 1351 1357
37. J.P. Machiels, S. Henry, and S. Zanetta Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01 J Clin Oncol 28 2010 21 28
38. S. Schmitz, M. Kaminsky-Forrett, and S. Henry Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02 J Clin Oncol 28 suppl 2010 abstr 5500
39. C.M. van Herpen, L.D. Locati, and J. Buter Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982) Eur J Cancer 44 2008 2542 2545
40. J. Martinez-Trufero, D. Isla, and J.C. Adansa Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment Br J Cancer 102 2010 1687 1691
41. J.P. Machiels, S. Subramanian, and A. Ruzsa Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial Lancet Oncol 12 2011 333 343
42. T.Y. Seiwert, P.M. Clement, and D. Cupissol BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study J Clin Oncol 28 suppl 2010 abstr 5501
43. A. Argiris, Y. Li, and A. Forastiere Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck Cancer 101 2004 2222 2229
44. R. Hitt, A. Irigoyen, and J. Nuñez Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC) J Clin Oncol 25 suppl 2007 abstr 6012
45. P. Ceruse, E. Lavergne, and G. Buiret Paclitaxel (TLX) and cetuximab (CTX) combination efficiency after failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC) J Clin Oncol 29 suppl 2011 abstr 5549
46. E. Guardiola, F. Peyrade, and L. Chaigneau Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer Eur J Cancer 40 2004 2071 2076
47. M.K. Gibson, and A.A. Forastiere Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art Curr Opin Oncol 16 2004 220 224
48. J.J. Sciubba End of life considerations in the head and neck cancer patient Oral Oncol 45 2009 431 434
49. P.D. Dios, and J.S. Lestón Oral cancer pain Oral Oncol 46 2010 448 451
50. V. Bar Ad, G. Weinstein, and P.R. Dutta Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy Cancer 116 2010 4206 4213
51. K.S. Chua, S.K. Reddy, M.C. Lee, and R.B. Patt Pain and loss of function in head and neck cancer survivors J Pain Symptom Manage 18 1999 193 202
52. D. Bouhassira, N. Attal, and H. Alchaar Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) Pain 114 2005 29 36
53. S. Salas, J.L. Deville, and R. Giorgi Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma Radiother Oncol 87 2008 195 200
54. E. Assenat, S. Thezenas, and N. Flori Prophylactic percutaneous endoscopic gastrostomy in patients with advanced head and neck tumors treated by combined chemoradiotherapy J Pain Symptom Manage 42 2011 548 556
55. B.M. Atasoy, O. Yonal, and B. Demirel The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy Eur Arch Otorhinolaryngol 269 2011 275 282
56. V. Martinez, N. Attal, D. Bouhassira, and M. Lantéri-Minet Les douleurs neuropathiques chroniques: diagnostic, évaluation et traitement en médecine ambulatoire. Recommandations pour la pratique clinique de la Société française d'étude et de traitement de la douleur Douleurs 11 2010 3 21
57. C.P. Watson, and N. Babul Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpeutic neuralgia Neurology 50 1998 1837 1841
58. J.S. Gimbel, P. Richards, and R.K. Portenoy Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial Neurology 60 2003 927 934
59. M. Hanna, C. O'Brien, and M.C. Wilson Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients Eur J Pain 12 2008 804 813
60. A. Gatti, A.F. Sabato, R. Occhioni, G. Colini Baldeschi, and C. Reale Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study Eur Neurol 61 2009 129 137
61. S. Salas, K. Baumstarck-Barrau, and M. Alfonsi Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: prospective randomized trial Radiother Oncol 93 2009 503 509
62. NCCN guidelines for head and neck cancers. Unresectable/recurrent/ persistent head and neck cancer; 2007. < www.nccn.org >.
63. L. Balducci, and M. Extermann Management of cancer in the older person: a practical approach Oncologist 5 2000 224 237
64. A.E. Stuck, A.L. Siu, and G.D. Wieland Comprehensive geriatric assessment: a meta-analysis of controlled trials Lancet 342 1993 1032 1036
65. A. Luciani, G. Ascione, and C. Bertuzzi Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13 J Clin Oncol 28 2010 2046 2050
66. P. Soubeyran, C. Bellera, and J. Goyard Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project J Clin Oncol 29 suppl 2011 abstr 9001
67. S.J. Lee, K. Lindquist, M.R. Segal, and K.E. Covinsky Development and validation of a prognostic index for 4-year mortality in older adults JAMA 295 2006 801 808
68. A. Hurria, H.J. Cohen, and M. Extermann Geriatric oncology research in the cooperative groups: a report of a SIOG special meeting J Geriatr Oncol 1 2010 40 44
69. A. Argiris, Y. Li, B.A. Murphy, C.J. Langer, and A.A. Forastiere Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy J Clin Oncol 22 2004 262 268
70. V. Launay-Vacher, S. Oudard, and N. Janus Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study Cancer 110 2007 1376 1384
71. V. Launay-Vacher, J.P. Spano, and N. Janus Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study Crit Rev Oncol Hematol 70 2009 124 133
72. L. Repetto, L. Biganzoli, and C.H. Koehne EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer Eur J Cancer 39 2003 2264 2272
73. V. Grégoire, J.L. Lefebvre, L. Licitra, and E. Felip Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 suppl 5 2010 v184 v186
74. L.Z. Rubenstein, K.R. Josephson, and G.D. Wieland Effectiveness of a geriatric evaluation unit. A randomized clinical trial N Engl J Med 311 1984 1664 1670